docetaxel anhydrous has been researched along with gemcitabine in 800 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (gemcitabine) | Trials (gemcitabine) | Recent Studies (post-2010) (gemcitabine) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 12,523 | 3,208 | 6,923 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | gemcitabine (IC50) |
|---|---|---|---|
| Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | 0.76 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 40 (5.00) | 18.2507 |
| 2000's | 364 (45.50) | 29.6817 |
| 2010's | 344 (43.00) | 24.3611 |
| 2020's | 52 (6.50) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, SY; Lee, HH; Liyanage, HDS; Mehta, SY; Pruijn, FB; Tercel, M; Youte Tendoung, JJ | 1 |
| Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Ettinger, DS | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Kennedy, MJ | 1 |
| Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M | 1 |
| Sculier, JP | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| Furuse, K | 1 |
| Negoro, S | 1 |
| Boyer, MJ | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Bunn, PA; Kelly, K | 1 |
| Rigas, JR | 2 |
| Carney, DN | 1 |
| Antoine, EC; Khayat, D | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| van Oosterom, AT | 1 |
| Rizvi, NA | 1 |
| Manegold, C | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Khattab, J; Urba, SG | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Akaza, H; Hattori, K | 1 |
| Ardiet, CJ; Bernard, E; Droz, JP; Guillot, A; Peguy, M; Rebattu, P; Tranchand, B; Zanetta, S | 1 |
| Kelly, K | 2 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Fukuoka, M | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Buccheri, G; Ferrigno, D | 1 |
| Sandler, A | 1 |
| Arita, K; Daido, K; Nakamura, K; Ohashi, N | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Heinemann, V | 5 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Georgoulias, VA | 1 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Malkowicz, SB; Vaughn, DJ | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Fine, RL; Sherman, WH | 1 |
| Botwood, N | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Mattson, K | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Murren, JR | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Gatzemeier, U | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Caffo, O | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| Kato, Y; Saijo, N | 1 |
| Morere, JF | 1 |
| Mavroudis, D | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Hensley, ML | 2 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Culine, S | 1 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Logothetis, C; Millikan, R | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Perez, EA; Qu, G | 1 |
| Green, MR | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Jacobs, AD | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 1 |
| Harper, P; Marx, G | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Besse, B; Spano, JP | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Terao, I | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Milandri, C; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Abbruzzese, JL | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Kalofonos, HP; Kosmas, C; Mylonakis, N; Tsavaris, N | 1 |
| Bunn, PA; Simon, GR | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Fumoleau, P | 1 |
| Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G | 1 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Bacoyiannis, C; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kiamouris, C; Klouvas, G; Kosmidis, P; Papakostas, P; Pavlidis, N; Samantas, E; Skarlos, DV | 1 |
| Alberola, V; Felip, E; Massuti, B; Rosell, R; Taron, M | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Haller, DG | 1 |
| Atadja, P; Bali, P; Bhalla, K; Donapaty, S; Fuino, L; Guo, F; Wang, HG; Wittmann, S; Yamaguchi, H | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Spiridonidis, CH | 1 |
| Calley, C; Fata, F; Ganjoo, KN; Loehrer, PJ; Picus, J; Schneider, BP; Seitz, DE; Stoner, C | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Andreola, G; Crucitta, E; D'Aprile, M; De Lena, M; Locopo, N; Lorusso, V; Marini, L; Silvestris, N | 1 |
| Anderson, N; Coco, F; Lokich, J | 1 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| Fukuchi, Y; Hirama, M; Ohhashi, R; Sato, K; Seyama, K; Suzuki, K; Takagi, Y; Takahashi, K; Uekusa, T | 1 |
| O'Shaughnessy, J | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C | 1 |
| Becht, C; Culine, S; Cupissol, D; Fabbro, M; Pinguet, F; Pouessel, D; Romieu, G; Ychou, M | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
| Israel, V; Jeffers, S; Raghavan, D; Snyder, T; Tagawa, ST | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Carrell, D; Drengler, RL; Greco, FA; Hainsworth, JD; Scroggin, C | 1 |
| Agelaki, S; Georgoulias, V; Kentepozidis, N; Kouroussis, C; Milaki, G; Palamidas, F; Papakotoulas, P; Polyzos, A; Syrigos, K; Tzanakis, N; Vamvakas, L; Veslemes, M | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Im, MM; Ostruszka, L; Robinson, BW; Shewach, DS | 1 |
| Brandi, M; Colucci, G; Gebbia, N; Giotta, F; Lopez, M; Schittulli, F; Valerio, MR; Vici, P | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martn-Richard, M; Mayordomo, JI; Pelegrí, A; Vázquez, S; Virizuela, J | 1 |
| Alexopoulos, A; Karamouzis, MV; Rigatos, G | 1 |
| Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P | 1 |
| Yardley, DA | 1 |
| Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
| Aviles, V; Benson, AB; Berlin, JD; Harris, JE; Levy, DE; Shepard, RC; Stuart, K; Thomas, JP | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Cheng, ZW; Zhang, L | 1 |
| Barceló, JR; López-Vivanco, G; Muñoz, A | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
| Barón, MG; Belón, J; Casado, E; De Castro, J; Dorta, J; Feliu, J; Gallurt, PM; Lizón, J; Lorenzo, A; Madroñal, C; Morales, S | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Hirai, I; Kawago, M; Kokawa, Y; Nishida, M; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T; Yuzaki, M | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Reddy, KG | 1 |
| Androulakis, N; Christophilakis, Ch; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Malamos, N; Mavroudis, D; Milaki, G; Polyzos, A; Varthalitis, I | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Herzog, TJ | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Akita, H | 1 |
| Alexopoulos, A; Ardavanis, A; Kandylis, C; Lainakis, G; Rigatos, G; Tryfonopoulos, D | 1 |
| Seidman, AD | 1 |
| Bastert, G; Hamerla, R; Huober, J; Lichter, P; Schneeweiss, A; Wallwiener, D | 1 |
| Belani, CP; Eckardt, J | 1 |
| Dumontet, C; Sève, P | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Agelidou, A; Anagnostopoulou, O; Androulakis, N; Ardavanis, A; Chatzidaki, D; Christou, A; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mixalopoulou, P; Polyzos, A; Samaras, N; Samonis, G; Syrigos, K; Toubis, M; Tsiafaki, X; Ziotopoulos, P | 1 |
| Braun, D; Breton, JL; Castéra, D; Clary, C; Debieuvre, D; Depierre, A; Gervais, R; Janicot, H; Kessler, R; Lemarié, E; Milleron, B; Morère, JF; Moro-Sibilot, D; Pujol, JL; Quantin, X; Rebattu, P; Souquet, PJ; Spaeth, D | 1 |
| Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T | 1 |
| Fukuoka, M; Furukawa, M; Hirashima, T; Kamoi, H; Kobayashi, M; Kudoh, S; Matsui, K; Mukohara, T; Nakagawa, K; Negoro, S; Nitta, T; Ogata, Y; Shiraishi, S; Takada, M; Takeda, K; Yamauchi, S; Yana, T; Yoshimura, N | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Barlési, F; Pujol, JL | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Ueoka, H | 1 |
| Lutz, MP | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Philip, PA | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M | 1 |
| Dieing, A; Eggemann, H; Elling, D; Flath, B; Hauptmann, S; Heilmann, V; Jehn, C; Krocker, J; Kümmel, S; Lehenbauer-Dehm, S; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Wischnewsky, MB | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Ando, S; Iida, T; Kimura, H; Nakajima, T; Suzuki, M | 1 |
| Cao, CW; Gao, Y; Guo, J; Shi, ZQ; Zhu, CL | 1 |
| De Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Highley, MS; Maes, RA; van Oosterom, AT | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Büchler, MW; Büchler, P; Eibl, G; Friess, H; Hines, OJ; Isacoff, WH; Reber, HA; Roth, MA | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Edelman, MJ | 1 |
| Kuramoto, K; Terao, I | 1 |
| Barth, RJ; Bettmann, MA; Cates, JM; Colacchio, TA; Cole, BF; Gordon, SR; Marshall, JF; McDonnell, CE; Meyer, LP; Perez, RP; Pipas, JM; Redfield, N; Ripple, GH; Suriawinata, AA; Sutton, JE; Tsapakos, MJ; Zaki, B | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Gajewski, BJ; Mayo, MS | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Fumoleau, P; Levy, C | 1 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Fahlke, J; Florschuetz, A; Greiner, C; Hahnfeld, S; Hribaschek, A; Kettner, E; Klein, H; Kuhn, R; Lippert, H; Manger, T; Meyer, F; Ridwelski, K; Wilhelm, G | 1 |
| Lorusso, V | 1 |
| Canil, C; Chi, KN; Moore, M; Murray, RN; Tinker, A; Winquist, E | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Bay, JO; Blay, JY; Brain, E; Bui, NB; Cherix, S; Chevreau, C; Cioffi, A; Coindre, JM; Emile, G; Fayette, J; Isambert, N; Kwiatkowski, F; Le Cesne, A; Leyvraz, S; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Muss, HB; Perez, E | 1 |
| Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Belani, CP | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P | 1 |
| Alcaide García, J; Alés Díaz, I; Benavides Orgaz, M; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Villar Chamorro, E | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Fournel, P | 1 |
| Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD | 1 |
| Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Carrato Mena, A; Gallego Plazas, J; Guillén Ponce, C; Maciá Escalante, S; Martínez Ortiz, MJ; Rodríguez Lescure, A | 1 |
| Smith, IE | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Favaretto, AG | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Li, M; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhang, Z | 1 |
| Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Androulakis, N; Boukovinas, I; Georgoulias, V; Gioulmbasanis, I; Kalykaki, A; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Polyzos, A; Vamvakas, L; Xenidis, N; Ziras, N | 1 |
| Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Beinert, T; Binder, D; Grah, C; Schäper, C; Schweisfurth, H; Siebert, G; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Ameshima, S; Chiba, Y; Demura, Y; Ishizaki, T; Miyamori, I; Nakanishi, M; Umeda, Y | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y | 1 |
| Aerts, R; De Boeck, G; De Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Martens, M; Selleslach, J; van Oosterom, AT | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Meerum Terwogt, JM; Rodenhuis, S; Schellens, JH; van Boven, HH; van den Heuvel, MM; Veltkamp, SA | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Adelstein, D; Davis, M; Kalmadi, S; McNeill, G; Mekhail, T; Peereboom, D | 1 |
| Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Scott-von-Römer, K | 1 |
| Astoul, P; Auquier, P; Barlési, F; Barrau, K; Doddoli, C; Morange, S; Thirion, X; Thomas, P | 1 |
| Magee, CC; Mendez, GP; Rennke, HG; Schlondorff, JS | 1 |
| Habuchi, T; Inoue, T; Kakinuma, H; Kanzaki, M; Kumazawa, T; Narita, S; Saito, M; Tsuchiya, N; Yuasa, T | 1 |
| Bessho, A; Isobe, H; Katakami, N; Niitani, H; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Blackstock, AW; Capellari, J; Knight, SN; Lovato, J; Miller, AA; Miller, MS; Mosley, L; Petty, WJ; Tucker, R | 1 |
| Foo, KF; Ho, J; Leong, SS; Lim, WT; Lin, X; Poon, D; Tan, EH; Tan, SB; Tay, MH; Toh, CK | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Calvo, I; Carrasco, E; Casado, V; Casillas, M; Díaz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; San Antonio, B; Sánchez-Rovira, P | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Borel, C; Calais, G; Cupissol, D; Eymard, JC; Germann, N; Kohser, F; Labourey, JL; Tourani, JM; Tubiana-Mathieu, N | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Gemma, A; Kawakami, A; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Noro, R; Ogawa, N; Seike, Y; Shionoya, A | 1 |
| Bookman, MA | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Chouaid, C; Fournel, P; Gimenez, C; Jullian, H; LeCaer, H; Letreut, J; Paillotin, D; Perol, M; Thomas, P; Vergnenegre, A | 1 |
| Chang, SY; Chang, WS; Kang, CY; Kim, YJ; Kim, YS; Ko, HJ; Ko, SY; Sakaguchi, S | 1 |
| Abou-Alfa, GK; O'Reilly, EM | 1 |
| Kim, CH; Kim, HS; Kim, JH; Kim, KJ; Lee, KY; Sung, CW | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Xu, BH | 1 |
| Burks, T; Chaudhary, UB; Curry, N; Sawhney, R | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kotsakis, A; Mavroudis, D; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N | 1 |
| Maki, RG | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Buesa, JM; Capelan, M; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Jiménez, P; Jiménez-Lacave, A; Llorente, B; Luque, M; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Ann Houston, G; Anthony Greco, F; Bearden, JD; Farley, C; Gandhi, J; Hainsworth, JD; Shipley, DL; Spigel, DR | 1 |
| Bailly, C; Bay, JO; Cabrespine, A; Gilliot, O; Gimbergues, P; Mishellany, F; Vincent, C | 1 |
| Charpidou, A; Dannos, I; Dilana, K; Dionellis, G; Georgatou, N; Karapanagiotou, E; Rigopoulou, A; Roussos, C; Syrigos, KN | 1 |
| Baldazzi, V; Carini, M; Crisci, A; Giordano, C; Grifoni, R; Lapini, A; Neri, B; Pantaleo, P; Raugei, A; Vannini, L | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Balani, JP; Mohanty, SK; Parwani, AV | 1 |
| Fornier, MN; Hudis, C; Kelsen, DP; Lefkowitz, R; O'Reilly, E; Patil, S; Rathkopf, D; Schwartz, GK; Shah, M; Tse, AN | 1 |
| Cucherat, M; Douillard, JY; Fossella, F; Georgoulias, V; Kubota, K; Kudoh, S; Laporte, S; Monnier, A; Pujol, JL; Rubio, JE | 1 |
| Albertsson, M; Friesland, S; Frykholm, G; Johansson, B; Kadar, L; Letocha, H; Wagenius, G | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| Raj Pandey, K | 1 |
| Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Di Marsico, R; Fabbri, A; Falcone, A; Innocenti, F; Lo Dico, M; Tartarelli, G; Tibaldi, C; Vasile, E | 1 |
| Begum, M; Bepler, G; Simon, GR | 1 |
| Brown, RK; Glaros, S; Michael, C; Reisman, D; Wilson, R | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Fukushima, M; Hamada, C; Hosoe, S; Kawahara, M; Matsui, S; Tada, H | 1 |
| Fujiwara, K; Ichikawa, K; Ishida, S; Kurakata, S; Yada, A; Yazawa, M; Yoshida, H | 1 |
| An, CH; Cho, EK; Hong, J; Jeong, SH; Kim, Y; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Abulafia, O; Blessing, JA; Degeest, K; Hensley, ML; Homesley, HD; Rose, PG | 1 |
| Boukovinas, I; Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Mendez, P; Rosell, R; Souglakos, J; Stathopoulos, E; Taron, M; Tripaki, M | 1 |
| Alexandrova, EN; Istomin, YP; Petrovich, SV; Sergeyeva, OP; Zhavrid, EA | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Daw, NC; Furman, W; McCarville, MB; Navid, F; Roberts, W; Watkins, A; Willert, JR | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Agelaki, S; Agelidou, A; Boukovinas, I; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, A; Mavroudis, D; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Fleming, G | 1 |
| Blessing, JA; Hensley, ML; Mannel, R; Rose, PG | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Cereda, S; Reni, M | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Bloom, C | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Kijima, H; Kusumi, T; Nakamura, M; Nishime, C; Ohnishi, Y; Sato, F; Suemizu, H; Tamaoki, N; Ueyama, Y; Yamazaki, H | 1 |
| Boukovinas, I; Georgoulias, V; Koutsopoulos, A; Mavroudis, D; Mendez, P; Papadaki, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Souglakos, J; Staphopoulos, E; Taron, M; Trypaki, M | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Abu-Rustum, N; Aghajanian, CA; Hensley, ML; Ishill, N; Konner, J; Larkin, J; Sabbatini, P; Soslow, R; Spriggs, D; Tew, W | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L | 1 |
| Ando, M; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Semba, H; Shibata, T; Takada, Y; Takeda, K; Tamura, T; Yokota, S | 1 |
| Blatter, J; Fossella, F; Hanna, N; Peterson, P; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K | 1 |
| Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y | 1 |
| Caraglia, M; Correale, P; Francini, G; Gotti, G; Macrì, P; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tindara Miano, S | 1 |
| Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Crinò, L; De Marinis, F; Falcone, A; Grassivaro, N; Nardi, M; Novello, S; Rinaldi, M; Russo, F; Scagliotti, GV; Tibaldi, C; Tinazzi, A; Tonato, M | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Gorlick, R; O'Day, K | 1 |
| Cruz, O; de Torres, C; Mora, J; Parareda, A; Sola, T | 1 |
| Barneto, I; Blanco, R; Catot, S; Chaib, I; Cobo, M; de Las Peñas, R; Diz, P; Domine, M; Ibeas, R; Isla, D; Jimenez, U; Lopez-Vivanco, G; Macias, JA; Mendez, P; Moran, T; Oramas, J; Perez-Roca, L; Provencio, M; Reguart, N; Rosell, R; Sala, MA; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tsakalaki, E | 1 |
| Adachi, S; Akiyama, M; Fujita, H; Hosokawa, K; Itani, Y; Ito, K; Tabata, T; Takeuchi, S; Tsubamoto, H | 1 |
| Brandi, M; Colucci, G; Corsetti, S; DI Lauro, L; Fattoruso, SI; Foggi, P; Gebbia, V; Giannarelli, D; Giotta, F; Lopez, M; Lorusso, V; Sergi, D; Vici, P; Viola, G; Vitucci, C | 1 |
| Agatsuma, T; Fujimoto, K; Hanaoka, M; Koizumi, T; Kubo, K; Urushihata, K; Yamamoto, H; Yasuo, M | 1 |
| Gkini, E; Gkiozos, I; Katirtzoglou, N; Kotteas, E; Makrilia, N; Ralli, M; Syrigos, K; Tourkantonis, I | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Alberola, V; Camps, C; Carcereny, E; Cobo, M; de Aguirre, I; Domine, M; Isla, D; Lopez-Vivanco, G; Massuti, B; Mendez, P; Moran, T; Okamoto, T; Provencio, M; Ramirez, JL; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Wei, J | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Halldén, G | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Puglisi, F | 1 |
| Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Gao, F; Leong, SS; Lim, WT; Ngeow, J; Poon, D; Tan, EH; Toh, CK | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, AG; Simou, E | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y | 1 |
| Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
| Bircan, HA; Ceyhan, AM; Karayigit, DZ; Yildirim, M | 1 |
| Dong, X; English, JC; Evans, K; Flint, J; Gout, PW; Guan, J; Lam, S; Lam, WL; Laskin, J; Ling, V; Macaulay, C; Murray, N; Ng, RT; Wang, Y; Yee, J | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Ardavanis, A; Arnogiannaki, N; Doufexis, D; Kountourakis, P; Maliou, S; Missitzis, I; Pissakas, G; Sotiropoulou, A; Zobolas, V | 1 |
| Agatsuma, T; Ichiyama, T; Koizumi, T; Kubo, K; Tanabe, T; Yamamoto, H | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Inhorn, RC; Lane, CM; Reeves, J; Rubinsak, J; Spigel, DR; Thompson, DS; Vazquez, ER; Webb, C | 1 |
| Abulafia, O; Blessing, JA; Miller, BE; Richards, WE; Secord, AA; Shahin, MS; Stehman, FB; Van Le, L; Warshal, DP; Yamada, SD | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Dickson, NR; Foust, JT; Grapski, R; Hainsworth, JD; Hendricks, LK; Peacock, NW; Scott, WL; Vázquez, ER; White, MB; Yardley, DA | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Kang, WK; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, JY; Park, SH; Park, YS | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| Kasman, I; Plowman, GD; Roy Choudhury, K | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D | 1 |
| Hayashi, T; Kakuta, Y; Nakai, Y; Nakao, A; Nakayama, M; Nonomura, N; Okumi, M; Takayama, H | 1 |
| Alberto, M; Alessandro, C; Artioli, G; Borgato, L; Bozza, F; Cappetta, A; Davide, P; Fernando, B; Giorgio, Z; Grazia, A; Lucia, B; Marchet, A; Mocellin, S; Pastorelli, D; Simone, M; Stefania, Z; Zavagno, G; Zovato, S | 1 |
| Gordian, E; Miller, H; Ramachandran, K; Rocha-Lima, C; Singal, R | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Awasthi, N; Brekken, RA; Kirane, A; Schwarz, MA; Schwarz, RE; Toombs, JE | 1 |
| Carron, MA; Kucuk, O; Lin, HS; Shkoukani, MA; Tulunay, O | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
| Halim, A; Wahba, H | 1 |
| Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalykaki, A; Karampeazis, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Vamvakas, L; Vardakis, N | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Collins, IM; Thomas, DM | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Gnant, M; Goetzinger, P; Koelblinger, C; Kuehrer, I; Sahora, K; Schindl, M | 1 |
| Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Alberts, SR; Camoriano, JK; Enger, JR; Farr, GH; Johnson, DB; Kim, GP; Morlan, BW; Reid, JM; Seay, TE | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Hashimoto, S; Hirai, Y; Kawago, M; Naito, K; Nakamura, R; Nishiguchi, H; Ohta, F; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Chan, S; Davidson, SE; Harden, S; McMahon, T; Paul, J; Rai, D; Reed, NS; Symonds, RP | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Arias-Pulido, H; Bocklage, T; Cerilli, LA; Eberhardt, S; Lee, SJ; Movva, S; Muller, CY; Purdy, M; Quinn, R; Rabinowitz, I; Schmit, B; Snyder, D; Verschraegen, CF | 1 |
| Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Bertucci, F; Cauvin, C; Chetaille, B; Denoux, Y; Guiramand, J; Hilgers, W; Jacquemier, J; Moureau-Zabotto, L; Sarran, A | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Milleron, B; Quoix, E; Westeel, V; Zalcman, G | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY | 1 |
| Dees, EC | 1 |
| Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Blenc, AM; Boxwala, I; Chisti, MM; Jaiyesimi, I; Micale, MA; Muslimani, A | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Du, Z; Shi, M; Xu, X; Yu, Y | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Alazraki, A; Brill, P; Clark, D; George, BA; Katzenstein, HM; Martin, M; Olson, TA; Qayed, M; Rapkin, L; Wasilewski-Masker, K | 1 |
| Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N | 1 |
| Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
| Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
| Chen, SW; Chu, PH; Huang, YK; Lu, MS; Shen, WC; Shih, LG | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A | 1 |
| Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A | 1 |
| He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H | 1 |
| Akinfenwa, PY; Anderson, ML; Creighton, CJ; Kolomeyevskaya, N; Laucirica, R; Lev, DC; Odunsi, K; Savannah, KB; Shan, W; Thomas, DG | 1 |
| Eskander, RN; Guo, Y; Hoang, B; Randall, LM; Sakai, T; Zi, X | 1 |
| Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N | 1 |
| Gradishar, WJ | 1 |
| Amoroso, D; Camerini, A; Cappuzzo, F; D'Incecco, A; Fabbri, A; Tibaldi, C; Vasile, E | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Baker, LH; Crowley, JJ; Maki, RG | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Belli, C; Cereda, S; Reni, M | 1 |
| Eshun, F; Hingorani, P; Watanabe, M; White-Collins, A | 1 |
| Chen, S; Cheng, YL; Gu, B; Li, ST; Ni, YJ | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Alvarez, R; Aribi, A; Chan, KT; Doan, NB; Gery, S; Ho, Q; Koeffler, HP; Lee, DH; Lee, K; Said, JW; Thoennissen, GB; Thoennissen, NH; Toh, M | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH | 1 |
| Lim, YL; Tay, EY | 1 |
| Kakimoto, M; Kawashima, H; Koshiishi, H; Miyamoto, H; Okamura, T | 1 |
| Araujo, DM; Baker, LH; George, S; Hensley, ML; Maki, RG; Priebat, DA; Soslow, RA; Sutton, G; Wathen, JK | 1 |
| Babu, R; Byrne, AT; Devocelle, M; Gallagher, WM; Kenny, ST; Nikodinovic-Runic, J; O'Connor, A; O'Connor, KE; O'Connor, S; O'Donovan, N; Szwej, E; Zinn, M; Zulian, QR | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Aigner, J; Jäger, D; Lorenzo Bermejo, J; Marmé, F; Schneeweiss, A; Sinn, P; Sohn, C | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Angspatt, A; Sriussadaporn, S | 1 |
| Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Dolgikh, SD; Gapbarov, ACh; Polysalov, VN; Veriasova, NN | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Ji, M; Li, J; Zhu, LN | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Ando, R; Etani, T; Hashimoto, Y; Kawai, N; Kohri, K; Naiki, T; Okada, A; Okamura, T; Tozawa, K; Yasui, T | 1 |
| Fan, KX; Guo, YJ; Huang, A; Wang, B; Zhang, B; Zhang, F | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
| Ahuja, N; Azad, NS; Danilova, L; Delmas, A; Herman, JG; Pelosof, L; Yerram, SR | 1 |
| Dong, X; Du, J; Hao, Y; Wei, Y; Yin, Q; Zhao, X | 2 |
| Kok, VC; Li, MC; Ruan, CW; Tsai, HJ | 1 |
| Egerer, G; Ho, AD; Kosely, F; Schmier, JW; Schmitt, T; Wuchter, P | 1 |
| Eberhart, C; Goldberg, MF; Hsu, AW; Montaner, S; Sodhi, A | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Kolek, V | 1 |
| Lopes, Gde L | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nagata, C; Nagumo, Y; Nishiyama, H; Oikawa, T; Suetomi, T; Uchida, M | 1 |
| Stinchcombe, TE | 1 |
| Celano, P; Eisenhauer, E; Fader, AN; Frasure, H; Gehrig, PA; Giuntoli, RL; Havrilesky, LJ; Krill, L; Levinson, K; Lopez, MA; Ricci, S; Secord, AA; Tanner, EJ | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Ito, K; Kaiho-Sakuma, M; Kurosawa, H; Nagai, T; Nagase, S; Niikura, H; Otsuki, A; Otsuki, T; Shiga, N; Shigeta, S; Takano, T; Tanaka, S; Tokunaga, H; Toyoshima, M; Tsuji, K; Utsunomiya, H; Yaegashi, N; Yamaguchi, T | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV | 1 |
| Gisbert, R; Gómez-Codina, J; Juan, O; Maciá, S; Muñoz, J; Vidal, J | 1 |
| Adams, S; Baum, J; Fitzgerald, JB; Harms, BD; Iadevaia, S; Jiao, Y; Johnson, BW; Kohli, N; Lugovskoy, AA; Nielsen, UB; Olivier, KJ; Razlog, M; Rennard, R; Rimkunas, V; Schoeberl, B; Tang, J; Xu, L | 1 |
| Horibe, K; Maeda, N; Moritani, S; Sekimizu, M; Ueki, H; Yamashita, Y | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Liu, S; Nielsen, DL; Nielsen, TO; Wallden, B | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N | 1 |
| Baumgartner, S; Kunz, M; Urech, K; Weissenstein, U | 1 |
| Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Ai, B; Cheng, G; Nie, X; Zhang, S | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Kim, DH; Lee, JA; Lim, JS; Seo, J; Song, BS; Yoo, JY | 1 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER | 1 |
| Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL | 1 |
| Abe, H; Kondo, Y; Miura, T; Nemoto, K; Nomura, S; Shioji, G; Tsuboi, N | 1 |
| Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Han, ZF; Hong, J; Jiang, Y; Liu, LS; Shen, LP | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Barth, RJ; Colacchio, TA; Gardner, TB; Gordon, SR; Hessami, N; Klibansky, DA; Mody, K; Pipas, JM; Putra, J; Ripple, GH; Smith, KD; Suriawinata, AA; Tsapakos, MJ; Tsongalis, GJ; Zaki, B | 1 |
| Andreou, D; Busemann, C; Ehninger, G; Gerdes, S; Pink, D; Reichardt, P; Richter, S; Schuler, MK; Tunn, PU | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Kaddis, N; Saif, MW | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Al Husaini, H; ALHusaini, H; Aparisi, F; Arriola, E; Baize, N; Ballesteros, I; Barneto, I; Berchem, G; Bernabé, R; Blasco, A; Bombaron, P; Bosch-Barrera, J; Botia-Castillo, M; Bover, I; Calvo de Juan, V; Camps, C; Carcereny, E; Catot, S; Chaib, I; Chen, H; Chen, X; Chouaid, C; Cobo, M; Colinet, B; Dansin, E; De Grève, J; de Las Peñas, R; Domine, M; Drozdowskyj, A; Du, J; Felip, E; Fournel, P; Fraboulet, G; Gao, Y; García-Campelo, MR; García-Girón, C; García-Gómez, R; Garcia-Sevila, R; Garde, J; Gasco, A; Germonpre, P; Gervais, R; Gil, J; González-Larriba, JL; Hernando-Polo, S; Hominal, S; Hu, J; Hu, W; Insa, A; Isla, D; Jantus, E; Jiménez, B; Kahlout, S; Karachaliou, N; Kong, W; Lecaer, H; Lena, H; LeTreut, J; Li, L; Li, R; Li, X; Lianes, P; Liu, B; Liu, J; Locher, C; López-López, R; López-Martín, A; Lopez-Vivanco, G; Lu, H; Macias, JA; Majem, M; Marti-Ciriquian, JL; Massuti, B; Mate, JL; Mijangos, E; Molinier, O; Monnet, I; Montoyo, R; Morales-Espinosa, D; Moran, T; Moreno, MA; O'Brate, R; Ocaña, J; Oliviero, G; Pallares, C; Parera, M; Pereira, E; Perez-Cano, M; Pérez-Carrión, R; Porta, R; Provencio, M; Qian, X; Ramirez, JL; Rauh, S; Reguart, N; Ren, W; Robinet, G; Rosell, R; Rosillo, F; Sala, MA; Sanchez, JJ; Sanchez, JM; Sanchez-Rodriguez, B; Sanchez-Ronco, M; Schoot, R; Shao, J; Song, Y; Sullivan, I; Sun, X; Taron, M; Terrasa, J; Thomas, P; Tierno-Garcia, M; Trigo, JM; Valdivia, J; Vergnenegre, A; Viñolas, N; Viteri, S; Wang, L; Wei, J; Wen, L; Wu, Q; Xiao, X; Xu, X; Yan, J; Yang, J; Yang, M; Yang, Y; Yin, J; You, C; Yu, L; Yue, X; Zhang, F; Zhang, J; Zhou, Y; Zhu, L; Zou, Z | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Azam, S; Batra, U; Choudhury, KD; Doval, DC; Kumar, K; Mehta, A; Pruthi, A | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Li, QH; Liu, P; Sun, L; Zhang, P; Zhou, DS | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Emmanouilidis, Ch; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katsaounis, P; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Nintos, G; Polyzos, A; Stoltidis, D; Vamvakas, L; Vaslamatzis, M; Vetsika, EK | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Bakkum-Gamez, JN; Behbakht, K; Hensley, ML; Mannel, RS; Michael, H; Miller, A; O'Malley, DM | 1 |
| Itagaki, T; Kameda, A; Kegoya, Y; Miyahara, E; Nitta, Y; Oue, N | 1 |
| Auquier, P; Barlesi, F; Chouaid, C; Crequit, J; Fabre-Guillevin, E; Le Caer, H; Le Treut, J; Legodec, J; Loundou, A; Pujol, JL; Simeoni, MC; Thomas, PA; Vergnenegre, A | 1 |
| Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A | 1 |
| Kord Valeshabad, A; Mieler, WF; Setlur, V; Shahidi, M; Thomas, M | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Alfredsson, J; Björklund, U; Bykov, VJ; Byström, S; Fransson, Å; Gullbo, J; Hallberg, A; Mohell, N; Uustalu, M; Wiman, KG | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
| Aksoy, A; Aliustaoglu, M; Alkis, N; Aydin, K; Dane, F; Demirci, NS; Ekinci, AS; Gumus, M; Inal, A; Inanc, M; Odabas, H; Sevinc, A; Turkeli, M; Ulas, A; Uysal, M; Yazilitas, D; Yuksel, S | 1 |
| Chan, A; De Guzman Langit, MR; Fong, W; Lim, ST; Lim, TA; Song, M; Tang, T; Tay, K | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Inatsu, H; Kondo, Y; Murata, T; Nyomura, S; Takahashi, N; Tokunaga, M; Tomita, K | 1 |
| Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
| Kim, DH; Kim, MS; Lee, JA; Lim, JS; Paik, EK; Seo, J; Yoo, JY | 1 |
| Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Nepple, KG; O'Donnell, MA; Steinberg, RL; Thomas, LJ; Velaer, KN | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Cheng, S; Coakley, N; Ellis, PM; Gregg, R; Kulkarni, S; Ung, YC; Vella, ET | 1 |
| Hori, K; Ito, K; Miyagi, K; Murakami, J; Nakagawa, M; Okubo, R; Shiomi, M; Tashima, R; Tsuruta, T; Uragami, K; Yoshioka, E | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Ahn, HS; Baek, HJ; Cho, WH; Choi, HS; Im, HJ; Jeon, DG; Kang, HJ; Koh, KN; Koo, HH; Kook, H; Lee, JA; Lee, JW; Lim, YJ; Park, BK; Park, HJ; Park, KD; Seo, JJ; Shin, HY; Song, WS; Sung, KW; Yoo, KH; Yoon, HS | 1 |
| Kitawaki, J; Kokabu, T; Konishi, E; Mori, T; Tsukasaki, N; Yasukawa, S | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Cassarino, D; Nguyen, CM | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Chuman, H; Hatano, H; Hiraga, H; Hosaka, M; Iwamoto, Y; Joyama, S; Kaya, M; Kubo, T; Morioka, H; Nagano, A; Nishida, Y; Takahashi, M; Tanaka, K; Toguchida, J; Tsumura, H; Yoshikawa, H | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Gajra, A | 1 |
| Agarwal, N; Agarwal, P; Baisre, A; Goldstein, IM; Hansberry, DR; Kavi, A | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Hayasaka, T; Honda, T; Imai, N; Kagabu, S; Kin, S; Matsui, T; Nishigori, H; Oishi, T; Otsuki, T; Sato, H; Sato, K; Shimokawa, H; Shoji, T; Sugiyama, T; Takahashi, F; Tando, T; Tokunaga, H; Wagatsuma, S; Watanabe, T; Watanabe, Y; Yaegashi, N; Yamada, H; Yamamoto, H; Yokoyama, Y; Yoshida, Y; Yoshinaga, K | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Becker, PS; Cassaday, RD; De Padova, N; Lindstrom, S; Puri, A; Ulrickson, ML | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Ahn, JH; An, H; Choi, Y; Kim, YH; Kim, YJ; Lee, J; Lim, HY; Lim, SH; Park, KH; Park, YS; Suh, DC; Yun, MS | 1 |
| Chiang, S; George, S; Hemming, ML; Hensley, ML; Nucci, MR; Wagner, AJ; Wang, L | 1 |
| Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Unno, M | 1 |
| Chung, JI; Hwang, H; Kim, TS; Noh, GH | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Embry-Schubert, J; Lentz, SE; Littell, RD; Neugebauer, R; Palen, TE; Raine-Bennett, T; Tucker, LY; Zaritsky, E | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Castañeda, A; Cruz, J; Cruz, O; de Alava, E; de Torres, C; Garcia Del Muro, X; Lopez-Pousa, A; Maradiegue, E; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Mora, J; Perez-Jaume, S; Valverde, C; Vaz, MA | 1 |
| Ding, T; Fan, Y; Gu, Z; Lin, G; Shi, Y; Wang, Q | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Fan, L; Song, C; Tan, J; Wu, H; Yang, Q; Zhao, S | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Chen, W; Feng, J; Huang, X; Liu, P; Shao, L; Sun, M; Sun, Q; Xiao, R; Xiong, J; Xiong, M; Yu, X; Yuan, W; Zhang, Q; Zhao, X | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
| Patel, JA; Piper, JB; Wang, BG | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Dora, CP; Gupta, RC; Jain, S; Katiyar, SS; Kumar Agrawal, A; Kushwah, V; Lamprou, DA | 1 |
| Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V | 1 |
| Nguyen, BD | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T | 1 |
| Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V; Lamprou, DA; Saraf, I; Singh, IP | 1 |
| Hu, C; Li, Y; Lu, X; Qian, W; Xu, T | 1 |
| Aujla, PK; Beckett, LA; Lara, PN; Li, Y; Pan, CX; Parikh, M; Robles, DA | 1 |
| Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J | 1 |
| Ahn, JB; Choi, YD; Chung, HC; Han, JW; Heo, SJ; Hur, H; Kim, HS; Kim, JH; Kim, KS; Kim, S; Kim, SH; Kim, SK; Lee, YH; Noh, SH; Park, HS; Rha, SY; Shin, KH; Suh, JS | 1 |
| Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Tian, Q; Wang, Y; Zhang, F | 1 |
| Asleh, K; Balslev, E; Burugu, S; Ejlertsen, B; Gao, D; Jensen, MB; Laenkholm, AV; Lyck Carstensen, S; Nielsen, DL; Nielsen, TO; Tykjaer Jørgensen, CL; Won, JR | 1 |
| Kopeček, J; Li, L; Opanasopit, P; Soodvilai, S; Wang, J; Yang, J | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Hashemi Sadraei, N; Patil, PD; Pennell, NA; Shapiro, M | 1 |
| Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Kawaguchi, K; Kiyuna, T; Kumamoto, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Gandara, DR; Knollmann, FD; Lim, S; Narayanan, A; Riess, JW; Walby, JAS | 1 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 1 |
| Enserro, D; Hensley, ML; Miller, DS | 1 |
| Kumar, S; Narain, TA; Sharma, G; Tyagi, S | 1 |
| Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z | 1 |
| Chen, J; Li, Z; Pan, Z; Yao, J; Yao, Z; Zhang, Y | 1 |
| Awasthi, A; Bill, KLJ; Brock, GN; Bupathi, M; Chen, JL; Demoret, B; Duggan, MC; Hays, JL; Millis, SZ; Pollock, RE; Seligson, ND; Shakya, R; Stets, CW; Timmers, CD; Wakely, PE | 1 |
| Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES | 1 |
| Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Chae, SH; Chang, M; Choi, AY; Kang, GG; Kim, SN; Lee, SJ; Shim, SH | 1 |
| Ai, P; Chen, N; Duan, B; Li, Y; Shi, H; Tian, J; Zhu, J | 1 |
| Barry, E; Bivalacqua, TJ; Daniels, MJ; Kates, M; Milbar, N; Sankin, A; Schoenberg, M | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Akita, H; Ando, R; Chaya, R; Etani, T; Iida, K; Kobayashi, D; Moritoki, Y; Nagai, T; Naiki, T; Nozaki, S; Okamura, T; Sugiyama, Y; Yanase, T; Yasui, T | 1 |
| Brooks, NA; O'Donnell, MA | 1 |
| Bi, PD; Duan, WJ; Liu, NQ; Ma, Y; Zhen, X | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L | 1 |
| Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H | 1 |
| Harano, K; Motohashi, T; Nakanishi, T; Saito, T; Susumu, N; Takehara, K; Teramoto, N; Tokunaga, H; Tsuda, H; Ueda, Y; Watanabe, R; Yamashita, N; Yokoyama, Y | 1 |
| Witjes, JA | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Huang, J; Li, Q; Liao, W; Wu, Q; Zhang, N; Zhang, P | 1 |
| Jeong, KC; Kwon, WA; Lee, SJ; Seo, HK | 1 |
| Hata, M; Kawana, K; Maebayashi, A; Nagaishi, M; Nakajima, T; Xiaoyan, T | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Li, C; Luo, S; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L | 1 |
| Babjuk, M | 1 |
| Búzová, D; Červený, J; Culig, Z; Drápela, S; Fedr, R; Hampl, A; Khirsariya, P; Krejčí, L; Paruch, K; Puhr, M; Souček, K; Suchánková, T; van Weerden, WM; Watson, WR | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Fukushima, T; Gomi, D; Hara, H; Kobayashi, T; Koizumi, T; Noguchi, T; Ozawa, T; Sekiguchi, N | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Bu, LP; Li, XY; Liu, H; Liu, P; Shao, L; Ying, Q; Yu, SQ | 1 |
| Fitzpatrick, FC; Sabile, JMG; Skelton, MR; Stump, MS | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Fujisaki, H; Hara, J; Hira, K; Ishii, Y; Matsubara, K; Nitani, C; Okada, K; Okuhiro, Y; Tanimura, K; Yamasaki, K | 1 |
| Asleh, K; Balslev, E; Gao, D; Jensen, MB; Leung, S; Lænkholm, AV; Nielsen, D; Nielsen, LB; Nielsen, TO; Riaz, N; Stovgaard, ES | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Black, PC; Roumiguié, M | 1 |
| Ando, R; Banno, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Nagai, T; Naiki, T; Naiki-Ito, A; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Tomiyama, N; Yasui, T | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Deng, H; Shen, Y; Shen, Z; Tang, M; Wei, Z; Zhou, C | 1 |
| Gu, HY; Hu, C; Huang, ZD; Lin, LL; Liu, ZZ; Wei, RX | 1 |
| Chen, Q; Li, S | 1 |
| Clark, PE; Meeks, JJ; Sexton, WJ | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Kavoussi, M; Nasrallah, AA; Williams, SB | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Amini, B; Araujo, D; Benjamin, RS; Cloutier, JM; Conley, AP; Feig, B; Keung, EZ; Lin, H; Livingston, JA; Ludwig, J; Nassif, EF; Patel, S; Ratan, R; Ravi, V; Roland, CL; Somaiah, N; Thirasastr, P; Wang, WL; Zarzour, MA; Zhou, X | 1 |
| Chevuru, PT; McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Araki, M; Kawada, T; Pradere, B; Shariat, SF; Yanagisawa, T | 1 |
| McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Hosseinifard, H; Hua, Z; Ijaz, I; Imani, S; Kahloon, LE; Liu, S; Sefidan, MO; Shahzad, MN; Zhang, YQ | 1 |
| Abbosh, P; Bell, S; Bukavina, L; Correa, AF; Kutikov, A; Magee, DE; Packiam, VT; Smaldone, M; Uzzo, R | 1 |
| Carducci, M; Chu, X; Crispen, P; Daneshmand, S; Hahn, N; Kates, M; Packiam, VT; Pietzak, E; Porten, S; Shevrin, DH; Smith, A; Wagner, LI; Westerman, ME; Williams, SB | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Bree, K; Davaro, F; Dinney, CP; Kamat, AM; Li, R; McElree, IM; Navai, N; O'Donnell, MA; Packiam, VT; Steinberg, RL; Tan, WS | 1 |
| Carvalho, FLF; Clinton, TN; Feldman, A; Hirsch, M; Kibel, AS; Melnick, K; Mossanen, M; Mott, SL; Mouw, KW; O'Donnell, MA; Preston, MA; Rizzo, N; Salari, K; Steele, GS; Wszolek, M; Wu, CL; Yim, K; Zafar, A | 1 |
176 review(s) available for docetaxel anhydrous and gemcitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[New promising anticancer drugs for lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
[New wave of chemotherapeutic agents: update in pulmonary oncology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
Chemotherapy in head and neck cancer. Overview of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Genetic testing for chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Genetic Testing; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Biosynthesis; Repressor Proteins; RNA, Messenger; Survival Analysis; Taxoids; Transcription Factors; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Antiblastic drug combinations with ifosfamide: an update.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Rationale for the use of gemcitabine in breast cancer (Review).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2004 |
[A case of primary squamous cell carcinoma of the lung with a metastatic thyroid tumor improved following chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Thyroid Neoplasms | 2004 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Taxoids | 2004 |
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Neoadjuvant Therapy; Taxoids | 2004 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine and docetaxel in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Taxoids; Time Factors; Treatment Outcome | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
What news in urological cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Palliative Care; Patient Selection; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Usefulness of predictive tests for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
[Strategy in the treatment of anthracycline-resistant breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
Pleomorphic leiomyosarcoma of the adrenal gland: case report and review of the literature.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyoma; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Nephrectomy; Radiotherapy, Adjuvant; Taxoids; Thrombophlebitis; Uterine Neoplasms | 2007 |
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vindesine; Vinorelbine | 2007 |
Role of gemcitabine in metastatic breast cancer patients: a short review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Survival Analysis; Taxoids; Tumor Suppressor Proteins | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
Novel therapeutic agents for osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Docetaxel; Dogs; Drug Delivery Systems; Folic Acid Antagonists; Gemcitabine; Humans; Immunologic Factors; Neoadjuvant Therapy; Neoplasm Proteins; Osteosarcoma; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Survival Rate; Taxoids; Xenograft Model Antitumor Assays; Young Adult | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung; Neoplasms; Regression Analysis; Taxoids | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Genital Neoplasms, Male; Humans; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Prostatectomy; Radiotherapy, Adjuvant; Seminal Vesicles; Taxoids; Treatment Outcome | 2011 |
Chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
Primary angiosarcoma of the breast: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
[LEIOMYOSARCOMA ARISING FROM OVARIAN VEIN WITH RIGHT HYDRONEPHROSIS: A CASE REPORT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hydronephrosis; Leiomyosarcoma; Ovarian Neoplasms; Taxoids; Tomography, X-Ray Computed; Vena Cava, Inferior | 2015 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Cystectomy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2016 |
The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Taxoids | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Primary Cutaneous Interdigitating Dendritic Cell Sarcoma: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Dendritic Cell Sarcoma, Interdigitating; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Skin Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2016 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Chemotherapy in Pancreatic Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Observational Studies as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2019 |
Combination Intravesical Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Successful surgical treatment of cardiac metastasis from uterine leiomyosarcoma: A case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Uterine Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Liposarcoma; Lung Neoplasms; Male; Orchiectomy; Testicular Neoplasms | 2020 |
Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2023 |
Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Proportional Hazards Models; Uterine Neoplasms | 2023 |
279 trial(s) available for docetaxel anhydrous and gemcitabine
| Article | Year |
|---|---|
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Methotrexate; Paclitaxel; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Taxoids | 1999 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2003 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms, Unknown Primary; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2004 |
Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Severity of Illness Index; Taxoids; Treatment Outcome | 2004 |
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Taxoids | 2004 |
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Survival Analysis; Taxoids | 2004 |
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Taxoids | 2004 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids | 2004 |
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Failure; United States | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2005 |
Neoadjuvant therapy with gemcitabine in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2004 |
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liposomes; Mastectomy, Segmental; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
[A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2005 |
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Conformal; Taxoids | 2005 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms | 2006 |
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Taxoids; Treatment Outcome; Urologic Neoplasms | 2006 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2007 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Survival; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2007 |
[Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids | 2006 |
Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids | 2006 |
A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2007 |
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2007 |
Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Pharyngeal Neoplasms; Recurrence; Taxoids; Treatment Outcome | 2007 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Staging; Patient Selection; Pleural Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2008 |
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2007 |
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids; Treatment Outcome | 2007 |
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2007 |
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Piperidines; Taxoids; Treatment Outcome | 2007 |
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Analysis; Taxoids | 2008 |
Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2008 |
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Research Design; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Taxoids; Uterine Neoplasms | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Uterine Neoplasms | 2009 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2009 |
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Recombinant Proteins; Taxoids; Treatment Outcome | 2009 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2009 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Topics: Adult; Aged; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Dosage Calculations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Histone Chaperones; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Pharmacogenetics; RNA, Messenger; RNA, Neoplasm; Survival Rate; Taxoids; Treatment Outcome | 2009 |
A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2009 |
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Taxoids | 2009 |
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Nicotinic; Survival Analysis; Taxoids | 2010 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nomograms; Radiotherapy, Adjuvant; Suramin; Taxoids; Treatment Outcome | 2010 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Patient Selection; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Tennessee; Treatment Outcome | 2010 |
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2010 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Taxoids | 2010 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Taxoids | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quality of Life; Taxoids; Uterine Cervical Neoplasms | 2011 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult | 2012 |
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids | 2011 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Infant; Male; Neoplasm Grading; Recurrence; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Time Factors | 2012 |
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Taxoids; Treatment Outcome; Uterine Neoplasms | 2013 |
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Survival Analysis; Taxoids | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
[Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Chronotherapy; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium; Young Adult | 2014 |
Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Flow Cytometry; Gemcitabine; Glutamates; Guanine; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Pemetrexed; Taxoids | 2013 |
Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Taxoids | 2014 |
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Precision Medicine; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Republic of Korea; Retrospective Studies; Survival Rate; Taxoids | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Taxoids; Treatment Outcome | 2014 |
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2014 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
[Effect of integrated Chinese medical treatment (as maintenance therapy) on the survival time of patients with advanced non-small-cell lung cancer: a clinical study].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Taxoids | 2014 |
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; China; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Male; Middle Aged; Nuclear Proteins; Taxoids; Treatment Outcome; White People | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-s
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Middle Aged; Neoplasm Metastasis; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Uterine Neoplasms | 2015 |
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Quality of Life; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome | 2015 |
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Odds Ratio; Prognosis; Prospective Studies; Sarcoma, Ewing; Spain; Survival Rate; Taxoids | 2017 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platinum Compounds; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Urologic Neoplasms | 2018 |
Clinical assessment of palliative radiotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Surveys and Questionnaires; Treatment Outcome | 2018 |
An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis | 2019 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
Topics: Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Prospective Studies; Retrospective Studies; Tumor Microenvironment | 2021 |
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
Topics: Aged; BCG Vaccine; Cohort Studies; Docetaxel; Female; Gemcitabine; Humans; Male; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies | 2023 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
349 other study(ies) available for docetaxel anhydrous and gemcitabine
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Drug Screening Assays, Antitumor; Duocarmycins; Female; Humans; Indoles; Mice; Mice, Nude; Nitro Compounds; Ovarian Neoplasms; Ovary; Pyrrolidinones | 2017 |
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured | 1997 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
[A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Topics: Annexin A5; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; Detergents; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Epothilones; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Multienzyme Complexes; Phosphorylation; Precipitin Tests; Proteasome Endopeptidase Complex; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sepharose; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2003 |
Special patients, special treatments.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Fever; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Population Dynamics; Taxoids | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-raf; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2004 |
Promising combination therapies with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Synergism; Gemcitabine; Histones; Humans; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Stem Cell Assay | 2004 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Neoplasms, Unknown Primary; Prognosis; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2004 |
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
[Histoculture drug response assay for solitary fibrous tumor--a case report].
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Diaphragm; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Muscle Neoplasms; Neoplasms, Fibrous Tissue; Taxoids | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; In Vitro Techniques; Male; Taxoids | 2005 |
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Topics: Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Recombinant Proteins; Taxoids; Time Factors; Trastuzumab | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Clinical Trials, Phase II as Topic; Computer Simulation; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Leiomyosarcoma; Organoplatinum Compounds; Oxaliplatin; Sample Size; Taxoids | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays | 2006 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptogenic Organizing Pneumonia; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Respiratory Insufficiency; Taxoids; Tomography, X-Ray Computed | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Taxoids; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2006 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Intramedullary metastases due to non microcytic lung carcinoma.
Topics: Adenocarcinoma; Bone Marrow Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Docetaxel; Frontal Lobe; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Taxoids; Thoracic Vertebrae; Vinblastine; Vinorelbine | 2006 |
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9 | 2006 |
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2006 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2007 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Ovarian Neoplasms; Respiratory Distress Syndrome; Severity of Illness Index; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
Electrolyte abnormalities and progressive renal failure in a cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Creatinine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Drug Administration Schedule; Fibrosarcoma; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Ifosfamide; Inflammation; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Renal Insufficiency; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 2007 |
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Docetaxel; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Topics: Adenoviridae; Animals; Antigens, CD; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Docetaxel; Doxorubicin; Female; Flow Cytometry; Galactosylceramides; Gemcitabine; Genetic Vectors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunization; Immunotherapy; Mice; Myeloid Cells; Peptide Fragments; Receptor, ErbB-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Transfection; Vaccines, DNA | 2007 |
Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Second; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Taxoids; Tomography, X-Ray Computed | 2008 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids | 2007 |
Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Hemangiosarcoma; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed | 2008 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hepatocytes; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids | 2008 |
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
Topics: Antineoplastic Agents; Carboplatin; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gemcitabine; HeLa Cells; Humans; Hyperthermia, Induced; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Taxoids; Temperature; Vinblastine; Vinorelbine | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Osteosarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Gemcitabine/docetaxel--welcome to a new standard.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leiomyosarcoma; Taxoids; Uterine Neoplasms | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Taxoids | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Breathless beyond obvious.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diagnosis, Differential; Docetaxel; Dyspnea; Endometrial Neoplasms; Female; Gemcitabine; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Taxoids | 2008 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Tumor Suppressor Proteins | 2008 |
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan | 2009 |
Treatment of disseminated paraganglioma with gemcitabine and docetaxel.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Paraganglioma; Taxoids | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Taxoids | 2009 |
[A squamous cell lung cancer patient who developed immune hemolytic anemia after gemcitabine and docetaxel administration].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Prednisone; Taxoids | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Quality of Life; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
Transverse leukonychia (Mees' lines) associated with docetaxel.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Nails; Nails, Malformed; Taxoids | 2010 |
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Precision Medicine; Taxoids; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2010 |
[A case of a pulmonary pleomorphic carcinoma with fever which responded well to chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids | 2010 |
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Peritoneal Neoplasms; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Models, Statistical; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
[A case of leiomyosarcoma of prostate: multimodality therapy suppressed disease progression for long term].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Prostatic Neoplasms; Taxoids | 2010 |
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Silencing; Humans; Pancreatic Neoplasms; Promoter Regions, Genetic; Taxoids; Transfection | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mitochondrial Proteins; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Survival Analysis; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Angiosarcoma of the scalp with complete response to a biweekly gemcitabine and docetaxel (GEMDOC) chemotherapy regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Scalp; Skin Neoplasms; Taxoids | 2011 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Taxoids | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2011 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Receptor, ErbB-2; Taxoids | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transdifferentiation; Chromosome Aberrations; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Gene Rearrangement, B-Lymphocyte; Humans; Hypopharyngeal Neoplasms; Immunophenotyping; Karyotyping; Langerhans Cell Sarcoma; Leukemia, Hairy Cell; Mutation; Neoplastic Stem Cells; Pyriform Sinus; Taxoids | 2012 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Right atrial angiosarcoma: rupture and tamponade.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiac Surgical Procedures; Cardiac Tamponade; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Heart Atria; Heart Neoplasms; Heart Rupture; Hemangiosarcoma; Humans; Male; Taxoids; Tomography, X-Ray Computed | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids | 2013 |
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Centrosome; Cyclohexanecarboxylic Acids; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Leiomyoma; Leiomyosarcoma; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Myometrium; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Taxoids; Thiazoles; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Drug Synergism; Female; Fibroblasts; Flavonoids; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leiomyosarcoma; Phytotherapy; Plant Extracts; Survivin; Taxoids; Uterine Neoplasms | 2012 |
Malignant fibrous histiocytoma of the ovary: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).
Topics: Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Taxoids | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Sarcoma; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Period; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Mice; Taxoids; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine | 2013 |
Toxic erythema of chemotherapy with periorbital and perioral involvement.
Topics: Antineoplastic Agents; Axilla; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Erythema; Female; Femur; Gemcitabine; Humans; Hyperpigmentation; Lung Neoplasms; Mouth; Orbit; Osteosarcoma; Taxoids; Treatment Outcome | 2012 |
[A case of recurrent breast cancer in which gemcitabine-docetaxel therapy was successful for a long period].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Recurrence; Taxoids; Time Factors | 2012 |
The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.
Topics: Anticarcinogenic Agents; Antimicrobial Cationic Peptides; Apoptosis; Biocompatible Materials; Biodegradation, Environmental; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Synergism; Fluorescent Antibody Technique; Gemcitabine; HeLa Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Microscopy, Confocal; Polyhydroxyalkanoates; Taxoids | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
[Regional chemotherapy in locally advanced and metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Primers; Docetaxel; Female; Gemcitabine; Gene Silencing; Humans; Mice; Microsatellite Instability; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Taxoids; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2014 |
Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Female; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
A large primary vaginal leiomyosarcoma diagnosed postoperatively and uterine leiomyomas treated with surgery and chemotherapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyoma; Leiomyosarcoma; Middle Aged; Taxoids; Uterine Neoplasms; Vagina; Vaginal Neoplasms | 2013 |
Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Choroidal Neovascularization; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Fluorescein Angiography; Gemcitabine; Humans; Male; Remission Induction; Taxoids; Tomography, Optical Coherence; Urethral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
[Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kidney Neoplasms; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Pancreatic Neoplasms; Taxoids | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Uterine Neoplasms | 2013 |
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leiomyosarcoma; Middle Aged; Sarcoma, Endometrial Stromal; Taxoids; Uterine Neoplasms | 2014 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Everolimus; Female; Gemcitabine; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Nuclear Proteins; Oncogene Proteins, Fusion; Remission Induction; Taxoids; Thoracic Neoplasms | 2014 |
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Messenger; Taxoids | 2014 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Herb-Drug Interactions; Humans; Male; Mitoxantrone; Neoplasms; Plant Extracts; Plants, Medicinal; Taxoids; Viscum album | 2014 |
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paxillin; Pyrimidines; Signal Transduction; src-Family Kinases; Taxoids; Thiazoles; Topotecan | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
[Marked efficacy of multimodality therapy for ureteral cancer producing granulocyte colony-stmimulating factor].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Taxoids; Ureteral Neoplasms | 2014 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Diabetes Mellitus; Docetaxel; Fasting; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Paraneoplastic Syndromes; Retrospective Studies; Single-Blind Method; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
A report of sarcomatoid carcinoma of the gallbladder treated with palliative deocetaxel and gemcitabine chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Radiography; Taxoids | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids | 2014 |
Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Docetaxel; Drug Combinations; Drug Liberation; gamma-Cyclodextrins; Gemcitabine; Humans; Liposomes; Mice, Nude; Nanostructures; Osteosarcoma; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
[A case of pleomorphic malignant fibrous histiocytoma with multiple lung metastases with bilateral pneumothorax after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Male; Pneumothorax; Taxoids; Treatment Outcome | 2015 |
Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Staging; Neoplasms, Unknown Primary; Photoreceptor Cells, Vertebrate; Sarcoma; Taxoids; Tomography, Optical Coherence; Uveal Diseases; Vision Disorders; Visual Acuity | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Creatinine; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Glutathione; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein Folding; Quinuclidines; Random Allocation; Taxoids; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hemoglobins; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Treatment Outcome | 2015 |
Carotid artery inflammation associated with gemcitabine-based therapy: a special report.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteritis; Carotid Arteries; Carotid Artery Diseases; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Vasculitis | 2015 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobutanes; Deoxycytidine; Docetaxel; Drug Administration Schedule; Endostatins; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Perfusion Imaging; Recombinant Proteins; Taxoids; Tomography, Emission-Computed | 2015 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Osteosarcoma; Radiotherapy Dosage; Radiotherapy, Adjuvant; Republic of Korea; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
[A Case of Bilateral Pneumothorax after Chemotherapy for Uterine Leiomyosarcoma with Multiple Lung Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Pneumothorax; Taxoids | 2016 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Retrospective Studies; Taxoids | 2016 |
Primary osteosarcoma of the uterine corpus: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Lung Neoplasms; Middle Aged; Osteosarcoma; Taxoids; Treatment Outcome; Uterine Neoplasms | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Gemcitabine; Humans; Japan; Middle Aged; Neutropenia; Osteosarcoma; Pneumonia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome; Tubulin Modulators; Young Adult | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
Prognostic Differences: Epstein-Barr Virus-Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunocompromised Host; Leiomyosarcoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Prognosis; Retroperitoneal Neoplasms; Spinal Neoplasms; Taxoids | 2017 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Health Surveys; Humans; Japan; Leiomyosarcoma; Lymph Node Excision; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2017 |
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Taxoids; Young Adult | 2018 |
YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.
Topics: 14-3-3 Proteins; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Endometrial Stromal Tumors; Female; Gemcitabine; Gene Rearrangement; Humans; Middle Aged; Neoplasm Grading; Retrospective Studies; Taxoids | 2017 |
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Proliferation; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Imaging, Three-Dimensional; Leiomyosarcoma; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Red Fluorescent Protein; Stomach Neoplasms; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Liposomes; Nanostructures; Prodrugs; Taxoids; Triple Negative Breast Neoplasms | 2017 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Ternary cocktail nanoparticles for sequential chemo-photodynamic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Taxoids | 2017 |
Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Flavanones; Gemcitabine; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Taxoids | 2017 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Follicular dendritic cell sarcoma of the porta hepatis.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Biomarkers, Tumor; Cholangiopancreatography, Endoscopic Retrograde; Dendritic Cell Sarcoma, Follicular; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2018 |
Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Topics: Albumins; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clathrin; Deoxycytidine; Docetaxel; Drug Carriers; Female; Gemcitabine; Hemolysis; Humans; Macromolecular Substances; MCF-7 Cells; Nanoparticles; Neoplasm Transplantation; Particle Size; Polymers; Protein Conformation; Rats; Rats, Sprague-Dawley | 2018 |
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Micelles; Nanoparticles; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Gastrointestinal: CT and PET/CT imaging of splenic littoral cell angiosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Docetaxel; Gemcitabine; Hemangioma; Hemangiosarcoma; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Splenectomy; Splenic Neoplasms | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Urologic Neoplasms | 2018 |
Implication of linker length on cell cytotoxicity, pharmacokinetic and toxicity profile of gemcitabine-docetaxel combinatorial dual drug conjugate.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Drug Combinations; Female; Gemcitabine; Hemolysis; Humans; Polyethylene Glycols; Rats, Sprague-Dawley; Taxoids | 2018 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, High-Energy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Ulcer | 2018 |
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis | 2018 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2019 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Nestin; Phosphoric Monoester Hydrolases; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs.
Topics: Antigens, CD20; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Pyrimidines; Serum Albumin, Human | 2019 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Heterografts; Humans; Leiomyosarcoma; Mice; Mice, Nude; Neoplasm Metastasis; Peritoneal Neoplasms; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Burden | 2019 |
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Deoxycytidine; Docetaxel; Drug Resistance; Drug Substitution; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Treatment Outcome | 2019 |
Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma.
Topics: Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Uterine Neoplasms | 2019 |
Reply to F. Tomao et al.
Topics: Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma | 2019 |
Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy.
Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Kidney Neoplasms; Leiomyosarcoma; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography | 2019 |
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docetaxel; Epirubicin; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Polyethyleneimine; Viral Proteins | 2019 |
Degree of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Amplification; Humans; Liposarcoma; Mice; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Surgical Procedures, Operative; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Topics: Animals; Arginine; Argininosuccinate Synthase; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Disease Models, Animal; Docetaxel; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Biological; Neoplasms; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2019 |
An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate; Urologic Neoplasms | 2019 |
MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; Neoplasm Proteins | 2020 |
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms | 2020 |
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate | 2019 |
Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; L-Lactate Dehydrogenase; Leiomyosarcoma; Middle Aged; Neoplasm Staging; Prognosis; Progression-Free Survival; Retrospective Studies; Uterine Neoplasms; Young Adult | 2020 |
Editorial Comment.
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Health Facilities; Humans; Urinary Bladder Neoplasms | 2020 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Markov Chains; Middle Aged; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Transcriptome; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome | 2020 |
Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, SCID; Mitosis; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyrimidines; S Phase; Xenograft Model Antitumor Assays | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2020 |
Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Plant Extracts; Poly (ADP-Ribose) Polymerase-1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2020 |
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel.
Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans | 2021 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
[Gemcitabine and Docetaxel for the Treatment of Relapsed and Refractory Malignant Rhabdoid Tumor of Kidney and Atypical Teratoid Rhabdoid Tumor].
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Kidney; Rhabdoid Tumor; SMARCB1 Protein; Teratoma | 2021 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Integrins; Laryngeal Neoplasms; Male; Middle Aged; Nomograms; Prognosis; Proportional Hazards Models; Survival Analysis | 2022 |
m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Topics: Adenosine; Antineoplastic Agents; Deoxycytidine; DNA Copy Number Variations; DNA Methylation; Docetaxel; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Sarcoma | 2021 |
Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies | 2022 |
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Mycobacterium bovis; Urinary Bladder Neoplasms | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Docetaxel; Gemcitabine; Humans; Liposarcoma; Middle Aged; Retrospective Studies; Trabectedin | 2023 |
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Docetaxel; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2023 |
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2023 |
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Cost-Effectiveness Analysis; Docetaxel; Gemcitabine; Humans; Medicare; Neoplasm Invasiveness; Non-Muscle Invasive Bladder Neoplasms; United States; Urinary Bladder Neoplasms | 2023 |
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
Topics: Administration, Intravesical; BCG Vaccine; Clinical Trials, Phase III as Topic; Docetaxel; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2023 |
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Topics: Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Topics: Aged; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |